Teresa Harris Graham

What does patient safety actually mean? After our Patient Safety Day Daiichi Sankyo Europe GmbH, I am more convinced than ever: it is about seeing the whole person, not just the treatment. We were privileged to hear directly from Diana Dragu and Katharina Bauer about the realities shaping their lives during treatment – from fertility and lactation, to the safety of their families at home, to the need for honest conversations about future plans. These are not “side topics” – they are central to patient safety. Pharmacovigilance helps us capture these lived experiences and turn them into knowledge we can act on. Listening alone is not enough. It is our responsibility to ensure these insights lead to tangible changes – in how we design our studies, how we counsel patients, and how we make sure our approach to treatment considers real-world needs. I cannot emphasize enough that patient safety is truly a shared mission. From Medical Affairs to Pharmacovigilance, from clinical teams to affiliates, each of us plays an important role in making sure treatments are not only effective but also safe and supportive. To patients and families – what aspects of safety matter most to you during and after treatment? 

154

10 Kommentare

We never stop pushing the boundaries of science for lung cancer patients.   Earlier this week, our AstraZeneca team showed up in force at the World Conference on Lung Cancer #WCLC25, with 58 abstracts presented during the congress.   On the global stage, we showcased our robust portfolio and pipeline, including final overall survival (OS) data from the FLAURA2 Phase III study in EGFR-mutated non-small cell lung cancer. Patients on our medicine plus chemo experienced an overall median survival of nearly four years compared to just over three years on monotherapy. An estimated 63.1% of patients treated with the combination were alive at three years and 49.1% of patients were alive at four years. At 57% data maturity, patients also saw a reduced risk of death by 23% compared to monotherapy.   The FLAURA2 regimen has impacted thousands of people facing this disease since its approval in 2024. The latest data reinforces our two fundamental goals in treating lung cancer by extending survival and preserving quality of life. This combination therapy enables progress toward those goals, allowing physicians to tailor treatments to individual needs and support improved outcomes for patients.   It’s another win for the lung cancer community and a testament to how we’re delivering more for every patient at every stage:   🫁 Building on our legacy of backbone therapies with powerful new combinations 🫁 Looking for new ways to use immunotherapy and keep pushing innovation forward 🫁 Redefining cancer care and digging deeper with antibody drug conjugates (ADCs) 🫁 Following the science to learn what new molecules and approaches might offer   We’ll continue seizing the opportunity to see what’s possible with our medicines: stronger outcomes, extended survival, and allowing patients to experience more hope for tomorrow.   👉 Read more about the FLAURA2 OS results here: https://lnkd.in/esnQKCTz

191

1 Kommentar

At Boehringer Ingelheim, we understand that patients are experts in their lived experience of disease. Innovation must be seen from their perspective, from insights to impact - we call this #PatientPoweredProgress.    Earlier this summer, I sat down with Vicki Mooney and Jan Geissler, highly engaging patient advocates, to talk about how we can continue to shape a more patient-centric healthcare system, together. You can view our discussion on the future of patient-centric healthcare here:  https://lnkd.in/e2WP-eMi   I’d love to hear your thoughts on priorities for creating a more patient-centric healthcare system in the comments below.   #LifeForward #PatientEngagement #PatientCentricity

579

3 Kommentare

Americans pay more for their medicines today because entities that play no role in drug development, including big tax-exempt 340B hospitals, are using medicines to subsidize other parts of their business.     Our new “Meet Mark” campaign exposes these hospitals, clinics and their for-profit partners that buy medicines for as little as a penny and mark them up by thousands, pocketing the difference. Read more here: https://lnkd.in/eam2A4ZK It’s time to fix the 340B program and end the markup schemes that are driving up costs for patients, taxpayers and employers.

101

9 Kommentare

👁️ All eyes on pubs! 📰 In today’s evolving landscape, it’s not just about how many—it’s about how much value a publication brings. As our very own David Ginkel shared on the latest In Plain Cite episode, the focus is shifting from Impact Factor to broader impact: how publications support journals, inform MSLs' interactions, and drive MI requests. 🤖 On the AI front, PLS tools are already in play, and exciting innovations like AI-assisted poster development and publication reformatting are on the horizon. But with great tech comes great responsibility—author agreements must evolve to keep pace. 🎧 Tune in for more insights: https://lnkd.in/er8BQmTU #MedicalAffairs #Publications #realworlddata #realworldevidence #rwe #rwd #data #healthcare #biopharma #ai #aihealthcare #patientcentricity #patientcare #scientificcommunications

39